Roche, the Swiss pharmaceutical giant, on Tuesday unveiled the latest clinical trial results for its experimental multiple sclerosis (MS) drug, fenebrutinib. The data positions the company to submit the treatment for regulatory approval, with the goal of reducing relapse rates and slowing the progression of disability in MS patients.
However, the path to approval remains uncertain. While three late-stage trials have demonstrated the drug’s efficacy, analysts and regulators are closely scrutinizing potential safety risks, particularly concerning liver function. This issue has previously led the U.S. Food and Drug Administration (FDA) to reject an MS therapy developed by Sanofi.
Adding to the concerns, researchers disclosed in the Tuesday data release that two patients died from drug-related causes while taking fenebrutinib. The deaths were reported during the clinical trials, raising further questions about the drug’s safety profile.
Fenebrutinib is designed to target BTK (Bruton’s tyrosine kinase), an enzyme implicated in the immune response linked to MS. If approved, it would join a growing class of MS treatments aimed at modifying the disease’s progression rather than merely managing symptoms.
The company’s next steps will depend on regulatory feedback, particularly regarding the safety signals observed in the trials. The FDA and other global health authorities will need to weigh the drug’s benefits against its risks before making a decision on approval.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...